Zealand Pharma A/S, a biotechnology company transforming the future of metabolic health, today presents its strategy for redefining the near-term future of weight management and its vision to establish leadership in metabolic health at its Capital Markets Day in London. The Company will unveil its comprehensive strategy that combines strategic partnerships, accelerated drug development, and expanded research capabilities to build the world’s most valuable metabolic health pipeline.
Zealand Pharma will target five launches, a robust clinical pipeline of more than ten programs, and industry-leading cycle times from idea to clinic by 2030. By leveraging its unrivaled peptide expertise, strengthened organization, and expanded global research capabilities, alongside advanced computational methods and partnerships, Zealand Pharma will accelerate its drug discovery process and expand its molecule-making toolbox. This strategic approach, combined with five anticipated launches from the existing pipeline and the Company's robust financial foundation, will optimally position Zealand Pharma to achieve leadership in metabolic health.
“Today marks a pivotal moment for Zealand Pharma as we unveil our aim to build a generational biotech company that will fundamentally transform how we treat obesity and metabolic disease,” said Adam Steensberg, Chief Executive Officer of Zealand Pharma. “We are redefining weight management for a new era - moving beyond the Weight loss Olympics toward solutions that support the everyday needs, aspirations, and overall well-being of people living with overweight, obesity, and metabolic imbalance.
“Through Metabolic Frontier 2030 and beyond, we are committed to addressing some of the greatest healthcare challenges of our time. Our strategy is built to enable multiple waves of innovation in metabolic health - from our foundational amylin franchise to breakthrough approaches that will not only shatter the adherence ceiling observed with current medicines in obesity but deliver a world-class metabolic health pipeline.
“By establishing a cutting-edge Boston research site, we are putting advanced automation and AI to work alongside more than 25 years of unmatched peptide expertise to accelerate drug discovery and development, while expanding our molecule-making toolbox. This includes advancing oral small-molecule receptor agonists through our collaboration with OTR Therapeutics for validated targets within Zealand Pharma’s established areas of biological expertise. Together, these initiatives - with more to come - enable us to deliver on our strategy and continue advancing innovative solutions for people with overweight, obesity, and metabolic imbalance.”
